Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy
Asia Pacific Allergy
;
(4): 126-128, 2014.
Article
in English
| WPRIM
| ID: wpr-749980
ABSTRACT
Anaphylaxis is a fatal and systemic allergic reaction, which can be prevented by avoiding exposure to a causative agent. However, the causative agent cannot be identified in all cases and may be hardly avoided. A 41-year-old man, diagnosed with idiopathic anaphylaxis, experienced 6 anaphylactic events over 7 months, requiring 4 emergency department (ER) visits and 3 epinephrine self-injections. Anti-immunoglobulin E (IgE) therapy was introduced to prevent further anaphylactic events. He experienced no anaphylactic events during 13 months of 4 monthly injections from the beginning until his most recent ER visit because of a similar anaphylactic event. We report a patient who experienced recurrent anaphylactic events that were prevented effectively by anti-IgE therapy with omalizumab. Anti-IgE therapy might be considered as an option to prevent anaphylactic events in patients for whom the causative agent(s) cannot be identified or avoided.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Immunoglobulin E
/
Epinephrine
/
Emergency Service, Hospital
/
Omalizumab
/
Distance Counseling
/
Hypersensitivity
/
Hypersensitivity, Immediate
/
Anaphylaxis
Limits:
Adult
/
Humans
Language:
English
Journal:
Asia Pacific Allergy
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS